HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China March 14, 2023
With a strong preclinical and clinical profile, fruquintinib offers a potential new treatment option for patients with refractory metastatic colorectal cancer (“CRC”), supporting the shared goal of ...